Therapeutic options in the treatment of psoriasis and atopic dermatitis - 21/08/11
Reprint requests: Alice B. Gottlieb, MD, PhD, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, CRC, 51 French St, New Brunswick, NJ 08901.New Brunswick, New Jersey
Résumé |
A variety of therapeutic options are available to treat psoriasis and atopic dermatitis (AD). Local agents typically are used to treat localized and milder forms of disease, whereas phototherapy and systemic agents are used for more generalized and severe disease. Various combinations and sequences of topical or systemic therapies, or both, have been utilized in the treatment of psoriasis and, less frequently, of AD. Conventional systemic therapies for psoriasis, such as corticosteroids, oral calcineurin inhibitors, antimetabolites, and retinoids, are limited by their propensity to cause serious side effects. More recently, a number of immunobiologic agents, such as monoclonal antibodies, recombinant cytokines, and fusion proteins, have been approved by the Food and Drug Administration or are undergoing development as systemic antipsoriatic treatments. In many of these categories, a number of exciting new therapies are in development that may augment the existing armamentarium available to clinicians for the treatment of inflammatory skin diseases.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AD, APC, FDA, ICAM, IFN-γ, Ig, IL, IL-2R, IMP, LFA, MHC, PUVA, TCI, TCR, TH1, TH2, TIG, TNF-⍺, UVA, UVB
Plan
| This article is part of a supplement supported by Connetics Corp, Palo Alto, California. Financial disclosure: Dr Gottlieb receives research funding from Amgen, Biogen Idec, Centocor, Genentech, W. H. Conzen Chair in Clinical Pharmacology, Abbott Laboratories, Ligand Pharmaceuticals, Beiersdorf, Fujisawa Healthcare, Merck, and Celgene. She is a member of the speakers' bureau for Amgen, Biogen Idec, Wyeth Pharmaceuticals, and Centocor. She has current consulting agreements with Amgen, Biogen Idec, CellGate, Centocor, Genentech, Novartis AG; QUATRx Pharmaceuticals, Wyeth Pharmaceuticals, Schering-Plough, Eisai Inc, Celgene, Bristol-Myers Squibb Co, Beiersdorf, Warner Chilcott, Inc, and Abbott Laboratories. |
Vol 53 - N° 1S
P. S3-S16 - juillet 2005 Retour au numéro
Article précédent
- New strategies for optimizing the treatment of inflammatory dermatoses with topical corticosteroids in an era of corticosteroid-sparing regimens
- Mark Lebwohl, Sheila Fallon Friedlander
- Mechanisms of action of topical therapies and the rationale for combination therapy
- David A. Norris
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?